A Game-Changer in Liver Cancer Management: Atezolizumab-Bevacizumab Combination Extends Liver Cancer Patients’ Survival, Promises New Era in Treatment

With Atezolizumab-Bevacizumab combination median overall survival was 12 months  In patients with good liver function, survival was 21 months   A first-of-its-kind study in real world setting conducted in India by Asian Institute of Gastroenterology (AIG) and published in the Journal of ....

Continue reading